Thought leadership

Artificial intelligence (AI) is reshaping laboratory medicine, not as a distant promise, but as a practical tool improving diagnostics, workflows, and quality. Through collaborative development, rigorous validation, and a commitment to ethical innovation, Mayo Clinic Laboratories is implementing AI-driven solutions that enhance precision, reduce turnaround times, and empower laboratorians to focus on what matters most: patient care.

By Jack Gilligan • October 6, 2025

Learn five ways to accelerate diagnostic innovation while safeguarding patient trust, data integrity, and regulatory readiness.

By Jack Gilligan • September 30, 2025

Christopher Garcia, M.D., chief digital innovation officer at Mayo Clinic Laboratories, shares how laboratories can use AI to expand access to data, personalize care, and transform the future of diagnostics.

By Jack Gilligan • September 23, 2025

A random urine test panel aids in diagnosing mast cell activation syndrome (MCAS), a complex condition often misdiagnosed due to overlapping symptoms. The panel improves access, speeds up diagnosis, and enables individualized treatment by detecting key mast cell mediators.

By Chris Bahnsen • August 11, 2025

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed.

By Jessie Fenske • July 3, 2025

After years of misdiagnosis, Tyler Hart found answers at Mayo Clinic, discovering he had NF155-IgG4 autoimmune nodopathy instead of CIDP

By Jack Gilligan • March 10, 2025

In a Fierce Healthcare article, Dr. William Morice highlights AI, digital pathology, and mass spectrometry as key advancements revolutionizing healthcare diagnostics and treatment.

By Jack Gilligan • March 6, 2025

The third episode of “Life of a Specimen” video series discusses the integration that drives the development of innovative tests, including the movement disorders evaluation, at Mayo Clinic Laboratories.

By Robin Huiras • February 26, 2025

Justin Fugelsang and Zach Pedowitz have never met. Yet both young men were diagnosed with a rare form of Charcot-Marie-Tooth disease, called sorbitol dehydrogenase (SORD) deficiency, and both found clarity through Mayo Clinic Laboratories' innovative SORD testing. Their journeys inspire resilience, as Justin has channeled his emotions into guitar playing, and Zach has embraced educational leadership.

By Chris Bahnsen • January 13, 2025

New diagnostic tests specifically for conditions that predominantly or only affect women, such as autoimmune diseases and gynecological cancers, are empowering female patients and their physicians to make informed decisions.

By Robin Huiras • December 2, 2024

JoAnne Michael’s symptoms started with dizziness and forgetfulness before down spiraling into severe confusion, crying jags, and brain seizures. ER doctors at her local hospital initially thought she was on drugs. JoAnne, terrified, wondered if she was dying. Luckily, she had a guardian angel by her side: her mother, a retired nurse practitioner, who took her to Mayo Clinic, where the clinical experience and expertise of neurologist Andrew McKeon, M.B., B.Ch., M.D., helped give her a diagnosis and hope for a journey back to health.

By Chris Bahnsen • November 4, 2024

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

By Barbara J. Toman • October 21, 2024

Alicia Algeciras-Schimnich, Ph.D., discusses Mayo Clinic Laboratories’ new noninvasive plasma biomarker assay for Alzheimer’s disease, an accessible, highly accurate testing option for individuals age 50 and above who are experiencing mild cognitive impairment or early dementia. Positive test results can confirm amyloid beta pathology and facilitate access to disease-modifying therapies.

By Robin Huiras • April 9, 2024